108 related articles for article (PubMed ID: 38850717)
1. Spatiotemporal release of non-nucleotide STING agonist and AKT inhibitor from implantable 3D-printed scaffold for amplified cancer immunotherapy.
Wang H; Liu Z; Fang Y; Luo X; Zheng C; Xu Y; Zhou X; Yuan Q; Lv S; Ma L; Lao YH; Tao Y; Li M
Biomaterials; 2024 May; 311():122645. PubMed ID: 38850717
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway.
Cheng L; Zhang P; Liu Y; Liu Z; Tang J; Xu L; Liu J
Biomaterials; 2023 Oct; 301():122259. PubMed ID: 37531777
[TBL] [Abstract][Full Text] [Related]
3. Oxidation-Responsive PolyMOF Nanoparticles for Combination Photodynamic-Immunotherapy with Enhanced STING Activation.
Zhou Q; Dutta D; Cao Y; Ge Z
ACS Nano; 2023 May; 17(10):9374-9387. PubMed ID: 37141569
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment-Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy.
Liu D; Liang S; Ma K; Meng QF; Li X; Wei J; Zhou M; Yun K; Pan Y; Rao L; Chen X; Wang Z
Adv Mater; 2024 Feb; 36(6):e2304845. PubMed ID: 37723642
[TBL] [Abstract][Full Text] [Related]
5. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
6. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
7. Decomposable Nanoagonists Enable NIR-Elicited cGAS-STING Activation for Tandem-Amplified Photodynamic-Metalloimmunotherapy.
Guo X; Tu P; Wang X; Du C; Jiang W; Qiu X; Wang J; Chen L; Chen Y; Ren J
Adv Mater; 2024 May; 36(21):e2313029. PubMed ID: 38353366
[TBL] [Abstract][Full Text] [Related]
8. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.
Gu Z; Hao Y; Schomann T; Ossendorp F; Ten Dijke P; Cruz LJ
J Control Release; 2023 May; 357():531-544. PubMed ID: 37030544
[TBL] [Abstract][Full Text] [Related]
9. Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy.
Luo K; Li N; Ye W; Gao H; Luo X; Cheng B
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889509
[TBL] [Abstract][Full Text] [Related]
10. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.
Yin M; Hu J; Yuan Z; Luo G; Yao J; Wang R; Liu D; Cao B; Wu W; Hu Z
Cell Cycle; 2022 Apr; 21(8):767-779. PubMed ID: 35130108
[TBL] [Abstract][Full Text] [Related]
11. Metformin promotes cGAS/STING signaling pathway activation by blocking AKT phosphorylation in gastric cancer.
Shen Q; Yang L; Li C; Wang T; Lv J; Liu W; Lin Y; Yin Y; Tao K
Heliyon; 2023 Aug; 9(8):e18954. PubMed ID: 37600406
[TBL] [Abstract][Full Text] [Related]
12. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
[TBL] [Abstract][Full Text] [Related]
13. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
[No Abstract] [Full Text] [Related]
14. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
15. STING activation in macrophages by vanillic acid exhibits antineoplastic potential.
Zhu M; Tang X; Zhu Z; Gong Z; Tang W; Hu Y; Cheng C; Wang H; Sarwar A; Chen Y; Liu F; Huo J; Wang X; Zhang Y
Biochem Pharmacol; 2023 Jul; 213():115618. PubMed ID: 37211172
[TBL] [Abstract][Full Text] [Related]
16. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
[TBL] [Abstract][Full Text] [Related]
17. Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS-STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy.
Dong W; Chen M; Chang C; Jiang T; Su L; Chen C; Zhang G
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762239
[TBL] [Abstract][Full Text] [Related]
18. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.
Zhang J; Yu S; Peng Q; Wang P; Fang L
Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538
[TBL] [Abstract][Full Text] [Related]
19. A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy.
Li Q; Dong Z; Cao Z; Lei H; Wang C; Hao Y; Feng L; Liu Z
ACS Nano; 2023 Jun; 17(11):10496-10510. PubMed ID: 37184402
[TBL] [Abstract][Full Text] [Related]
20. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
Xuan C; Hu R
ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
